Real-world data of anamorelin in advanced gastrointestinal cancer patients with cancer cachexia

Ari Nishimura,Satoshi Hamauchi,Akifumi Notsu,Kunihiro Fushiki,Kotoe Oshima,Takahiro Tsushima,Takeshi Kawakami,Akiko Todaka,Tomoya Yokota,Hirofumi Yasui,Yusuke Onozawa,Kentaro Yamazaki
DOI: https://doi.org/10.1186/s12904-024-01538-9
2024-08-27
BMC Palliative Care
Abstract:Cancer cachexia is characterized by the loss of body weight (BW) and anorexia. Anamorelin (ANAM) is a selective ghrelin receptor agonist with appetite-enhancing anabolic action. The ONO-7643-05 trial demonstrated that ANAM increased lean body mass and improved anorexia in a Japanese population. However, the clinical outcomes of patients on ANAM have not yet been reported.
health care sciences & services,health policy & services
What problem does this paper attempt to address?